Q2 EPS Estimates for Bone Biologics Lifted by Zacks Research

Bone Biologics Corp. (NASDAQ:BBLG) – Zacks Research increased their Q2 2026 earnings per share (EPS) estimates for Bone Biologics in a research report issued on Friday, May 15th. Zacks Research analyst B. Sorensen now anticipates that the company will post earnings of ($0.39) per share for the quarter, up from their previous forecast of ($0.50). The consensus estimate for Bone Biologics’ current full-year earnings is ($1.93) per share. Zacks Research also issued estimates for Bone Biologics’ Q3 2026 earnings at ($0.36) EPS, Q4 2026 earnings at ($0.33) EPS, FY2026 earnings at ($1.52) EPS and FY2027 earnings at ($1.26) EPS.

Separately, Weiss Ratings raised Bone Biologics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Monday, April 27th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Bone Biologics currently has an average rating of “Sell”.

Bone Biologics Trading Up 0.9%

NASDAQ BBLG opened at $1.26 on Wednesday. Bone Biologics has a 1-year low of $1.05 and a 1-year high of $6.75. The stock has a 50-day moving average of $1.26 and a 200-day moving average of $1.48. The firm has a market cap of $2.27 million, a PE ratio of -0.56 and a beta of 0.89.

Bone Biologics (NASDAQ:BBLG) last released its earnings results on Thursday, May 14th. The company reported ($0.43) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.43).

Institutional Trading of Bone Biologics

A hedge fund recently raised its stake in Bone Biologics stock. DRW Securities LLC increased its stake in Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 23,576 shares of the company’s stock after buying an additional 12,549 shares during the period. DRW Securities LLC owned 1.31% of Bone Biologics worth $34,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 34.30% of the company’s stock.

About Bone Biologics

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.